Alector, Inc.: management transactions · United States · SEC (Form 4)

About Alector, Inc.

Alector, Inc. (NASDAQ: ALEC) is a clinical-stage biotechnology company headquartered in South San Francisco, California, in the United States. The company was originally formed as a Delaware LLC in May 2013 and later reorganized into Alector, Inc. in October 2017. For investors, Alector fits squarely into the high-risk, high-science biotech segment: it is not a commercial pharma company, but a research-driven developer focused on neurodegenerative disease programs with meaningful binary clinical catalysts. Alector’s core business is the discovery and development of therapies intended to treat brain disorders, with a particular emphasis on slowing the progression of neurodegenerative diseases and, ultimately, preventing them. Its central differentiator is the proprietary Alector Brain Carrier (ABC) platform, designed to improve delivery of therapeutics across the blood-brain barrier. Management has described ABC as adaptable across multiple therapeutic modalities, including antibodies, enzymes, and siRNA. That platform strategy is important from an investor perspective because successful brain delivery has long been one of the toughest challenges in neuroscience drug development. The company’s pipeline is concentrated in large, unmet-need indications such as Alzheimer’s disease, frontotemporal dementia, and broader neurodegenerative disorders. Historically, Alector collaborated with GSK on several programs, including nivisnebart (AL101/GSK4527226) and latozinemab (AL001). In October 2025, Alector and GSK reported topline Phase 3 INFRONT-3 results for latozinemab, and the trial did not meet its primary clinical endpoint. More recently, in May 2026, Alector said that an interim futility analysis led to discontinuation of the PROGRESS-AD Phase 2 study of nivisnebart in early Alzheimer’s disease. These updates are material because they show both the promise and the risk embedded in the company’s clinical portfolio. Alector’s competitive position is based less on current revenue generation and more on scientific differentiation, intellectual property, and the potential of its ABC platform to produce a pipeline of brain-penetrant assets. The company has highlighted preclinical and research programs such as AL137, an ABC-enabled anti-amyloid antibody, AL050, an ABC-enabled GCase enzyme replacement therapy, and additional siRNA programs in discovery or IND-enabling work. In other words, Alector is trying to convert a platform into multiple shots on goal. Geographically, Alector’s operations are primarily US-based, with corporate and development activities centered in California. The stock is listed on the NASDAQ market in the United States, which is consistent with its status as a development-stage biotech rather than a mature pharmaceutical manufacturer. Recent company communications in 2026 indicate that Alector still has substantial cash resources, but the strategic narrative has shifted after mixed late-stage clinical outcomes. For investors in France, Belgium, and Switzerland, Alector remains a watchlist name for exposure to the neurodegeneration theme, but one that requires careful attention to trial readouts, partnership dynamics, and capital allocation.